Literature DB >> 31692425

An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.

Aslı Gelincik1, Ozlem Cavkaytar2, Semanur Kuyucu3.   

Abstract

Severe cutaneous drug hypersensitivity reactions involve of different mechanisms , some of which are life-threatening, such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction and drug-induced vasculitis. These reactions may have substantial morbidity and mortality. In the past years, successive studies have provided new evidence regarding the pathogenesis of some of these severe reactions and revealed that underlying mechanisms are highly variable. Since these reactions have unique presentations and distinct pathomechanisms, the treatment methods and response rates might be different among various entities. Although supportive and local therapies are sufficient in some of these reactions, targeted immunosuppressive treatments and even mechanistic therapies such as plasmapheresis may be required in severe ones. However, there is still insufficient evidence to support the best treatment options for these patients since number of patients and large-scale studies are limited. In this review, conventional and new treatment options for severe cutaneous drug hypersensitivity reactions are presented in detail in order to provide the contemporary approaches to lessen the morbidity and mortality relevant to these severe iatrogenic diseases. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Severe cutaneous drug hypersensitivity; Stevens-Johnson syndrome/toxic epidermal necrolysis; acute generalized exanthematous pustulosis; corticosteroids; drug reaction with eosinophiliazzm321990and systemic symptoms; drug-induced vasculitis; generalized bullous fixed drug eruptions; intravenous immunoglobulin; management; serum sickness and serumzzm321990sickness-like reaction; treatment.

Mesh:

Year:  2019        PMID: 31692425     DOI: 10.2174/1381612825666191106115556

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  1 in total

1.  Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospital.

Authors:  Ali Nili; Ehsan Zarei; Azin Ghamari; Ali Salehi Farid; Soheil Tavakolpour; Maryam Daneshpazhooh; Hamidreza Mahmoudi
Journal:  Int Immunopharmacol       Date:  2020-10-19       Impact factor: 4.932

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.